77.50
-0.64 (-0.83%)
| Penutupan Terdahulu | 78.14 |
| Buka | 79.69 |
| Jumlah Dagangan | 240,330 |
| Purata Dagangan (3B) | 595,085 |
| Modal Pasaran | 2,925,448,704 |
| Harga / Buku (P/B) | 4.87 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -3.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.64% |
| Nisbah Semasa (MRQ) | 37.65 |
| Aliran Tunai Operasi (OCF TTM) | -101.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -66.74 M |
| Pulangan Atas Aset (ROA TTM) | -16.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.33% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Disc Medicine, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 10.65% |
| % Dimiliki oleh Institusi | 99.13% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 125.00 (Stifel, 61.30%) | Beli |
| Median | 114.50 (47.75%) | |
| Rendah | 109.00 (Wells Fargo, 40.65%) | Beli |
| Purata | 115.75 (49.36%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 86.37 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 16 Dec 2025 | 109.00 (40.65%) | Beli | 91.47 |
| Truist Securities | 10 Nov 2025 | 114.00 (47.11%) | Beli | 83.58 |
| Stifel | 03 Nov 2025 | 125.00 (61.30%) | Beli | 84.69 |
| Morgan Stanley | 30 Oct 2025 | 115.00 (48.40%) | Beli | 85.75 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |